Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Dec 3, 2021
Distillery Therapeutics

FBXL2-mediated EGFR degradation for TKI-resistant NSCLC

BioCentury | Oct 25, 2018
Distillery Therapeutics

Autoimmune disease

BioCentury | Mar 7, 2018
Distillery Therapeutics

Cancer

BioCentury | Feb 24, 2017
Clinical News

Prophage G-200: Ph II data

BioCentury | Jan 6, 2017
Clinical News

HS-410: Additional Ph I/II data

BioCentury | Dec 22, 2016
Product R&D

Fever pace for Zika

Zika’s momentum could push nucleic acid vaccines over the finish line
BioCentury | Oct 31, 2016
Company News

Heat Biologics, University of Miami deal

BioCentury | Oct 25, 2016
Clinical News

Heat, UMiami seek to create fetal Zika vaccine

BioCentury | Oct 17, 2016
Company News

Heat Biologics, Adaptive Biotechnologies deal

BioCentury | Sep 19, 2016
Clinical News

Viagenpumatucel-L: Phase Ib/II resumed

Items per page:
1 - 10 of 59